Claims
- 1. A method for diminishing the side effects of reintoid therapy in a patient in need thereof, comprising topically applying to an affected skin area of the pateint a dermatologically suitable composition comprising an effective amount of a natural EGFR inhibitor selected from the group consisting of genistein, genistin, quercetin, equol, staurosporine, aeroplysinin, indocarbazole, lavendustin, piceatannol, kaempferol, daidzein, erbstatin, and tyrphostins, and mixtures thereof and a suitable carrier, wherein the inhibitor is administered to the patient prior to retinoid therapy, during retinoid therapy, and/or after retinoid therapy.
- 2. The method of claim 1, wherein the retinoid used in the therapy is a natural retinoid.
- 3. The method of claim 2, wherein the retinoid is a natural retinoid selected from the group consisting of retinoic acid, all-trans retinoic acid, 13-cis retinoic acid, 9-cis retinoid acid, retinol, retinal, retinoic acid esters, and mixtures thereof.
- 4. The method of claim 1, wherein the retinoid used in the therapy is a synthetic retinoid.
- 5. The method of claim 4, wherein the retinoid is a synthetic retinoid selected from the group consisting of adapalene, tazarotene, and mixtures thereof.
- 6. The method of claim 1, wherein the retinoid therapy is for the treatment of a skin condition selected from the group consisting of acne, acne scarring, eczema, keratinization disorders, cancer, precancerous lesions, chemoprophylaxis, warts, sarcoidosis, treating photoaged skin, preventing photoaged skin, treating chronologically aged skin, preventing chronologically aged skin, post inflammatory hyperpigmentation, UV-induced loss of collagen biosynthesis, and combinations thereof.
- 7. The method of claim 1, wherein the natural EGFR inhibitor is present in the form of a compound, mixture, isolate, or extract that is derived from soy.
- 8. The method of claim 7, wherein the natural EGFR inhibitor is genistein, genistin, diadzein, or a mixture thereof.
- 9. The method of claim 8, wherein the EGFR inhibitor is derived from soy beans or soy bean curd.
- 10. The method of claim 1, wherein said inhibitor is applied at least prior to the retinoid therapy.
- 11. The method of claim 1, wherein said inhibitor is applied at least during the retinoid therapy.
- 12. The method of claim 11, wherein said retinoid and said inhibitor are combined in a single composition.
- 13. The method of claim 11, wherein the retinoid for the retinoid therapy is administered topically.
- 14. The method of ciaim 11, wherein the retinoid for the retinoid therapy is administered systemically.
PRIOR APPLICATIONS
This application is based on prior provisional application serial No. 60/271,894, filed Feb. 27, 2001, the disclosure of which is incorporated herein by reference.
US Referenced Citations (4)
Number |
Name |
Date |
Kind |
5665367 |
Burger et al. |
Sep 1997 |
A |
5824702 |
Wei |
Oct 1998 |
A |
6207667 |
Matsuno et al. |
Mar 2001 |
B1 |
6423747 |
Lanzendorfer |
Jul 2002 |
B1 |
Foreign Referenced Citations (5)
Number |
Date |
Country |
0 100 613 |
Feb 1984 |
EP |
DW 1995-027620 |
Nov 1994 |
JP |
2001 001 290 |
Jan 2001 |
KR |
WO 9813020 |
Apr 1998 |
WO |
WO 9936050 |
Jul 1999 |
WO |
Non-Patent Literature Citations (1)
Entry |
James Varani. “Heparin-Binding Epidermal-Growth-Factor-Like Growth Factor Activation of Keratinocyte ErbB Receptors Mediates Epidermal Hyperplasla, a Prominent Side-Effect of Retinold Therapy”. Journal of Investigative Dermatology,vol. 117, No. 6, 2001, Great Britian. |
Provisional Applications (1)
|
Number |
Date |
Country |
|
60/271894 |
Feb 2001 |
US |